Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

DiaMedica Therapeutics: Q2 Earnings Insights

  DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM.

Here’s what investors need to know about the announcement.

Earnings

DiaMedica Therapeutics beat estimated earnings by 27.78%, reporting an EPS of $-0.13 versus an estimate of $-0.18.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.08 which was followed by a 2.82% increase in the share price the next day.

 

To track all earnings releases for DiaMedica Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cereal Maker WK Kellogg Sticks To Annual Outlook Post Q1 Beat: Details

By Shivani Kumaresan
May 7, 11:57 AM
WK Kellogg exceeds expectations in Q1 FY24 with a 1.9% sales dip, reporting $707 million, surpassing analyst forecasts. Operating income surges 91.6% to $46 million, while adjusted EBITDA climbs 8.7% to $75 million. Chairman Gary Pilnick reaffirms strategic focus, projecting FY24 net sales growth of -1% to +1% and adjusted EBITDA growth of 3% to 5%, aiming for $265 million to $270 million.

KLG